Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

141. Cost-effectiveness of endoscopy in irritable bowel syndrome

Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Cost-effectiveness of endoscopy in irritable bowel syndrome Suleiman S, Sonnenberg A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology The use of flexible sigmoidoscopy and colonoscopy in the diagnosis of irritable bowel syndrome. Type of intervention Diagnosis. Economic study type Cost-effectiveness analysis. Study population The study investigated patients possibly suffering from IBS. Setting Hospital. The study was set in the USA. Dates to which data relate Effectiveness and resource use data were collected from studies published between 1977 and 1999. Cost data were taken from sources published

NHS Economic Evaluation Database.2001

142. Irritable bowel syndrome : guidelines for general practice

Irritable bowel syndrome : guidelines for general practice PRIMARY CARE SOCIETY FOR GASTROENTEROLOGY Irritable Bowel Syndrome: Guidelines for General Practice The strength of evidence for these statements or recommendations ranges from; A (randomised controlled trials), B (other controlled or quasi-experimental studies), C (descriptive studies) to D (expert opinion or clinical experience of respected authorities) Overview Irritable bowel syndrome (IBS) is a common, non-life threatening (...) condition affecting 1.5-2 times as many women as men. It is a chronic disorder that fluctuates in intensity and is characterised by visceral hypersensitivity. It is costly to the NHS and has a significant impact on quality of life affecting 17% of the UK population; three quarters of these rely on self-care. Clinical features IBS is characterised by the presence of abdominal pain associated with altered bowel habit in the absence of an identifiable structural or biochemical disorder. There are 4 key

Publication 10832001

143. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials

Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized controlled trials Jailwala J, Imperiale T F, Kroenke K Authors' objectives To evaluate the efficacy of pharmacological agents for the irritable bowel syndrome. Searching Articles published (...) ; and combinations of two to three of these agents. Co-interventions included dietary changes such as high fibre diet, and concurrent use of other medications. Participants included in the review Adult patients with irritable bowel syndrome were eligible. Mean age ranged from 24 to 51 years (median 38 years). An average of 68% of participants were women. The following means were used to diagnose irritable bowel syndrome: standard criteria (including the Rome and Manning criteria); operational criteria based

DARE.2000

144. Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome

Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome Lotronex (TM): therapy for diarrhea predominant irritable bowel syndrome McGahan L Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation McGahan L. Lotronex (TM): therapy for diarrhea predominant (...) irritable bowel syndrome. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation des Technologies de la Sante (CCOHTA) 2000: 4 Authors' objectives To summarise the available evidence on Lotronex (TM) for diarrhea predominant irritable bowel syndrome (IBS). Authors' conclusions Lotronex (TM) has been approved for marketing in the United States for the treatment of IBS in women whose predominant symptom is diarrhea. Lotronex (TM) has not yet

Health Technology Assessment (HTA) Database.2000

145. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial.

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. 10744088 2000 04 11 2000 04 11 2015 06 16 0140-6736 355 9209 2000 Mar 25 Lancet (London, England) Lancet Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. 1035-40 Irritable bowel syndrome (IBS) is a common gastrointestinal disorder with symptoms of abdominal pain, discomfort, and altered bowel function. Antagonists (...) of the type 3 serotonin receptor (5-HT3) have shown promising results in the relief of IBS-associated symptoms. We aimed to confirm these findings by doing a randomised, placebo-controlled trial. We studied 647 female IBS patients with diarrhoea-predominant or alternating bowel patterns (diarrhoea and constipation). 324 patients were assigned 1 mg alosetron and 323 placebo orally twice daily for 12 weeks, followed by a 4-week post-treatment period. Adequate relief of abdominal pain and discomfort

Lancet2000

146. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis

Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis Pittler M H, Ernst E Authors' objectives To review the clinical trials of extracts of peppermint (Mentha X piperita L.) as a symptomatic treatment for irritable bowel syndrome (IBS). Searching MEDLINE, EMBASE, BIOSIS Previews, and CISCOM were searched from (...) was given in three doses ranging from 0.2 to 0.4 mL. Participants included in the review The patients included in the trials had IBS. However, the authors stated that IBS was not diagnosed using accepted clinical features for IBS in 7 of the 8 included trials. Outcomes assessed in the review Global improvement of symptoms and adverse drug reactions was assessed. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many

DARE.1998

147. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial.

Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. 9820260 1998 11 25 1998 11 25 2016 10 17 0098-7484 280 18 1998 Nov 11 JAMA JAMA Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. 1585-9 Irritable bowel syndrome (IBS) is a common functional bowel disorder for which there is no reliable medical treatment. To determine whether Chinese herbal medicine (CHM) is of any benefit in the treatment of IBS (...) . Randomized, double-blind, placebo-controlled trial conducted during 1996 through 1997. Patients were recruited through 2 teaching hospitals and 5 private practices of gastroenterologists, and received CHM in 3 Chinese herbal clinics. A total of 116 patients who fulfilled the Rome criteria, an established standard for diagnosis of IBS. Patients were randomly allocated to 1 of 3 treatment groups: individualized Chinese herbal formulations (n = 38), a standard Chinese herbal formulation (n = 43), or placebo

JAMA1998

148. Abnormal colonic fermentation in irritable bowel syndrome.

Abnormal colonic fermentation in irritable bowel syndrome. 9777836 1998 11 04 1998 11 04 2015 06 16 0140-6736 352 9135 1998 Oct 10 Lancet (London, England) Lancet Abnormal colonic fermentation in irritable bowel syndrome. 1187-9 The cause of irritable bowel syndrome (IBS) is unknown. It may follow gastroenteritis and be associated with an abnormal gut flora and with food intolerance. Our study was designed to assess whether these factors were associated with colonic malfermentation. We carried (...) out a crossover controlled trial of a standard diet and an exclusion diet matched for macronutrients in six female IBS patients and six female controls. During the final 72 h on each diet, faecal excretion of fat, nitrogen, starch, and non-starch polysaccharide NSP was measured, and total excretion of hydrogen and methane collected over 24 h in a purpose-built 1.4 m3 whole-body calorimeter. Breath hydrogen and methane excretion were then measured for 3 h after 20 g oral lactulose. The maximum rate

Lancet1998

149. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials

Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials Talley N J, Owen B K, Boyce P, Paterson K Authors' objectives To determine whether psychological treatments are of value in irritable bowel syndrome (IBS). Searching The studies were identified by searching (...) MEDLINE from 1966 to 1994 and PsycLIT from 1974 to 1994, and by reviewing reference lists of relevant articles. Only English language publications were considered. Study selection Study designs of evaluations included in the review Only studies published in full, with a comparable control group, and assessment of IBS symptoms as the primary outcome measure, were included. Specific interventions included in the review Psychological management of IBS based on any of the following: cognitive

DARE.1996

150. Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome.

Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. 2563797 1989 03 30 1989 03 30 2015 06 16 0140-6736 1 8635 1989 Feb 25 Lancet (London, England) Lancet Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome. 424-5 33 patients with refractory irritable bowel syndrome were treated with four 40-minute sessions of hypnotherapy over 7 weeks. 20 improved, 11 of whom lost almost all their symptoms. Short-term improvement (...) methods Male Middle Aged Random Allocation Severity of Illness Index Time Factors 1989 2 25 1989 2 25 0 1 1989 2 25 0 0 ppublish 2563797 S0140-6736(89)90013-5

Lancet1989

151. Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome.

Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. 6150275 1985 01 14 1985 01 14 2015 06 16 0140-6736 2 8414 1984 Dec 01 Lancet (London, England) Lancet Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome. 1232-4 30 patients with severe refractory irritable-bowel syndrome were randomly allocated to treatment with either hypnotherapy or psychotherapy and placebo. The psychotherapy patients showed a small (...) England Lancet 2985213R 0140-6736 AIM IM Acute Disease Adult Clinical Trials as Topic Colonic Diseases, Functional physiopathology therapy Female Follow-Up Studies Gastrointestinal Motility Humans Hypnosis Male Middle Aged Psychotherapy Random Allocation Time Factors 1984 12 1 1984 12 1 0 1 1984 12 1 0 0 ppublish 6150275 S0140-6736(84)92793-4

Lancet1984

152. Controlled study of psychotherapy in irritable bowel syndrome.

Controlled study of psychotherapy in irritable bowel syndrome. 6136745 1983 10 08 1983 10 08 2015 06 16 0140-6736 2 8350 1983 Sep 10 Lancet (London, England) Lancet Controlled study of psychotherapy in irritable bowel syndrome. 589-92 101 outpatients with irritable bowel syndrome were randomly allocated to two treatment groups. Both groups received the same medical treatment, but patients in one group also received dynamically oriented individual psychotherapy in ten hour-long sessions spread

Lancet1983

153. Food hypersensitivity in irritable bowel syndrome.

Food hypersensitivity in irritable bowel syndrome. 6135828 1983 09 09 1983 09 09 2015 06 16 0140-6736 2 8345 1983 Aug 06 Lancet (London, England) Lancet Food hypersensitivity in irritable bowel syndrome. 295-7 Food hypersensitivity as a cause of abdominal symptoms was investigated by means of exclusion diets and double-blind food provocation in patients with irritable bowel syndrome. Twenty-seven patients entered the study; nineteen complied with dietary manipulation. Food hypersensitivity (...) as a cause of their presenting symptoms was confirmed by double-blind food provocation in only three patients, who also had evidence of associated atopic disease and positive skin tests to common inhalant allergens. Evidence of minor psychiatric disorder was found in twelve of fourteen patients examined by an independent psychiatrist. Bentley S J SJ Pearson D J DJ Rix K J KJ eng Clinical Trial Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 37341-29-0 Immunoglobulin E AIM IM

Lancet1983

154. Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome.

Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. 6128447 1983 01 19 1983 01 19 2015 06 16 0140-6736 2 8308 1982 Nov 20 Lancet (London, England) Lancet Food intolerance: a major factor in the pathogenesis of irritable bowel syndrome. 1115-7 Specific foods were found to provoke symptoms of irritable bowel syndrome (IBS) in 14 of 21 patients. In 6 patients who were challenged double blind the food intolerance was confirmed. No difference was detected in changes (...) in plasma glucose, histamine, immune complexes, haematocrit, eosinophil count, or breath hydrogen excretion produced after challenge or control foods. Rectal prostaglandin E2 (PGE2), however, increased significantly, and in a further 5 patients rectal PGE2 correlated with wet faecal weight. Food intolerance associated with prostaglandin production is an important factor in the pathogenesis of IBS. Jones V A VA McLaughlan P P Shorthouse M M Workman E E Hunter J O JO eng Clinical Trial Journal Article

Lancet1982

155. Wheat fibre and irritable bowel syndrome. A controlled trial.

Wheat fibre and irritable bowel syndrome. A controlled trial. 70639 1977 10 20 1977 10 20 2015 06 16 0140-6736 2 8035 1977 Aug 27 Lancet (London, England) Lancet Wheat fibre and irritable bowel syndrome. A controlled trial. 417-8 Twenty-six patients with irritable bowel syndrome entered a controlled trial of diets with a high or low wheat-fibre content. After 6 weeks on the high-wheat fibre regimen there was significant improvement in symptoms and an objective change in colonic motor activity (...) . No such improvement occurred on the low-fibre regimen. Patients with irritable bowel syndrome should be encouraged to increase their daily intake of wheat fibre. Manning A P AP Heaton K W KW Harvey R F RF eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Lancet 2985213R 0140-6736 9004-34-6 Cellulose AIM IM Adult Cellulose administration & dosage therapeutic use Clinical Trials as Topic Colon physiopathology Colonic Diseases, Functional diet therapy physiopathology Dietary

Lancet1977

156. A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome.

A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. 55586 1976 04 10 1976 04 10 2015 06 16 0140-6736 1 7954 1976 Feb 07 Lancet (London, England) Lancet A double-blind trial of the effect of wheat bran on symptoms of irritable bowel syndrome. 270-2 59 outpatients with irritable bowel syndrome participated in a randomised double-blind trial. The patients in the treatment group received three biscuits daily each containing 10 g of ordinary miller's bran (...) , whereas the patients in the control group received wheat biscuits of a similar appearance. The treatment period was 6 weeks. 52% of the patients in the treatment group noted subjective improvement compared with 65% in the control group. The results of this trial do not support the routine use of miller's bran in irritable bowel syndrome. Soltoft J J Krag B B Gudmand-Hoyer E E Kristensen E E Wulff H R HR eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial England Lancet

Lancet1976